Home / Pharmaceuticals / Opioid Induced Constipation (OIC) Drugs Market By Drug Type (Methylnaltrexone Bromide, Lubiprostone, Naloxegol, Naldemedine, Elobixibat, Alvimopan, Dolcanatide), By Prescription Type ( Prescribed Drugs) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Opioid Induced Constipation (OIC) Drugs Market By Drug Type (Methylnaltrexone Bromide, Lubiprostone, Naloxegol, Naldemedine, Elobixibat, Alvimopan, Dolcanatide), By Prescription Type ( Prescribed Drugs) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Published: Mar 2016 | Report Code: 57737-03-16

Global Opioid Induced Constipation (OIC) market is estimated to hit USD 2,779.24 Mn in 2022 with a CAGR of 4.6% during 2016-2022. Europe contributes highest in global OIC market in 2014 followed by North America. North America is expected to contribute significantly in OIC market and expected to hit USD 1,167.3 Mn in 2022 with highest CAGR 5.6% during 2016-2022. Germany is expected to contribute highest in European market and expected to hit USD 306.7 Mn in 2014. Introduction of several highly targeted, oral, peripherally acting mu-opioid receptor antagonist (PAMORA) therapies which are easily administrated with convenient dosing such as AstraZeneca’s Naloxegol, Cubist’s Bevenopran and Salix’s oral Relistor.

Launching of new OIC products, FDA approvals and success in clinical trials are driving the market. For example the launch of AMITZA across the EU and the approval of Linzess across the 6MM for OIC created scope for the market. It will enable to increase physician and patient awareness of non-laxative prescription options to treat constipation. High price of PAMORAs compared to other laxative therapies and reimbursement issues may affect the growth of OIC market. Patient and physician awareness is challenging for the growth of OIC drugs market.

Global Opioid Induced Constipation (OIC) is expected to grow significantly in the next few years due to significant adoption of OIC drugs for the treatment of chronic non-cancer pain. The FDA approvals and successful clinical trials of OIC drugs are driving the global OIC drugs market. For example FDA approvals such as Movantik/Moventig were approved by the US FDA and the EMA in 2014 has been driving the market. These drugs reduce the undesirable effects of the opioid analgesics without affecting its analgesic effects. As a result these drugs are increasingly becoming the preferred medication to treat opioid-induced constipation.

Opioid Induced Constipation (OIC) Market

Moreover, growing elderly population and rise in healthcare spending are creating huge scope for global Opioid Induced Constipation (OIC) drugs market. APAC is expected to emerge has a significant market following North America and Europe. Opioid Induced Constipation (OIC) and related diseases are caused by a poor diet, not drinking enough water and not passing stools on time. In the modern day scenario, poor food habits and sedentary work style have been instrumental in constipation problems. Coupled with these, regular use of Opioid drugs causes OIC.  As a result OIC diseases are much prevalent in developed nations such as the US, UK, Spain, France and Germany. Pregnancy, a lack of exercise or movement and some medication may also cause constipation. As a result there is significant demand of OIC drugs across the globe.

North America has highest has highest contribution in OIC drug market by over the counter drugs followed by Canada. Almost 50% of the US population has one or the other type of constipation problems. There is huge demand for prescribed and over the counter drugs in US, UK, France, Spain, Germany, China, India and Indonesia. Movantik, Methylnaltrexone and Lubiprostone are some common drugs widely adopted across the globe. Precautions must be taken before taking any such drugs. It is advised to avoid this medication if the patient is allergic to constipation drugs or any other medications. Patients are advised to tell about prescription and non-prescription medications, vitamins, nutritional supplements they are taking or planning to take in future. Side effects such as nausea, stomach pain, swelling of the face, tightness in throat, diarrhoea, gas, vomiting, dry mouth, runny nose, cough, fever, headache and so on may cause.

Research and development is driving the global OIC drugs market. Regular FDA approvals and success of pipeline drugs in clinical trials are creating huge scope for OIC drugs market. For example Naldemedine has successfully completed two phase 3 clinical trials for Opioid Induced Constipation (OIC) and is currently being evaluated in two phase 3 clinical trials for irritable bowel syndrome with constipation (IBS-C). OIC market is hopeful to get increasing successful clinical trials and FDA nod in near future at present the product is in third phase of the clinical trial. For instance, Shionogi & Co is hopeful and has intentions to file its first new drug application (NDA) with Naldemedine for OIC in 2016.

OIC drugs are used to relieve stomach pain, bloating, and straining and produce softer and more frequent bowel movements in patients suffering from OIC. It creates difficult or infrequent passage of stools, drugs such as Lubiprostone enables to provide relief for such conditions. In North America is used to treat irritable bowel syndrome with constipation IBS-C which causes stomach pain or cramps, bloating, and infrequent or difficult passage of stools in women who are at least 18 years of age. OIC drugs are widely adopted due to huge number of constipation patients and elderly patients are increasing globally.

Most of the patients take these drugs to get relief from constipation and the drugs enable them for smooth stools. However, there are some probable side effects that may affect the patient. The side effects are rare which includes nausea, stomach pain, swelling of the face, tightness in throat and so on. However, these are patient specific and far and few.  In the larger picture the OIC drugs are widely adopted and the rise in FDA approvals to the new drugs is creating huge scope for OIC drugs market. As a result, companies are focusing on research and development to come up with better drugs to deal with constipation. There are various drugs, laxatives available in the market which is used to get relief from constipation. Newer medications like Lubiprostone, Methylnaltrexone Bromide, Naloxegol and so on are widely adopted.

 

Chapter 1 Preface
1.1 Report Scope and Description
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Opioid Induced Constipation (OIC) Drugs Market Industry Snapshot

Chapter 3 Global OIC Drugs Market Analysis
3.1 OIC Drugs Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.1 Increasing Use of Opioid
3.3.1.2 Elderly Population
3.3.1.3 Rising Opioids Prescription in North America and Europe
3.3.1.4 Large Range of Effective OIC Drugs Available
3.3.2 Restraints
3.3.2.1 Research on Pain and Next Generation Analgesics
3.3.2.2 Adverse Effects of OIC Drugs
3.3.2.3 Unawareness and hesitation among patients
3.3.2.4 Large number of considerations while using opioids
3.3.3 Opportunities
3.3.3.1 Emerging APAC Market
3.3.3.2 Rising Use of Opioids
3.4 Attractive Investment Proposition, 2015
3.5 Market Positioning of Key OIC Drugs Manufacturers

Chapter 4 Global OIC Drugs Market, by Drug Type
4.1 Overview
4.2 Methylnaltrexone Bromide
4.3 Lubiprostone
4.4 Naloxegol
4.5 Pipeline Drug Analysis: Phase 3: Naldemedine (Year of Launch to 2022 (USD Mn)
4.6 Pipeline Drug Analysis: Phase 3: Elobixibat (Year of Launch to 2022 (USD Mn)
4.7 Pipeline Drug Analysis: Phase 2: Alvimopan, Dolcanatide (Qualitative Information)

Chapter 5 Global OIC Drugs Market, by Prescription Type
5.1 Overview
5.2 Prescribed Drugs
5.2.1 Prescribed OIC Drugs Market, by Prescription Type 2014-2022 (USD Mn)
5.2.2 Prescribed OIC Drugs Market, by Prescription Type, 2014-2022 (USD Mn)
5.2.2.1 Prescribed Branded OIC Drugs Market 2014-2022 (USD Mn)
5.2.3 Over the Counter Drugs

Chapter 6 Global OIC Drugs Market, by Geography
6.1 North America
6.1.1 U.S.
6.1.2 Canada
6.2 Europe
6.2.1 U.K.
6.2.2 Germany
6.2.3 Rest of the Europe
6.3 Asia Pacific
6.3.1 China
6.3.2 Japan
6.3.3 Rest of Asia Pacific (APAC)
6.4 Rest of the World (ROW)
6.4.1 Middle East and Africa
6.4.2 Latin America
6.4.3 Rest of the ROW

Chapter 7 Company Profiles
7.1 Astrazenenca
7.1.1 Overview
7.1.2 Astrazeneca Product Portfolio
7.1.3 SCOT Analysis
7.2 Shionogo & Co Ltd
7.2.1 Overview
7.2.2 Shionogi product portfolio
7.2.3 Scot Analysis
7.3 Salix Pharmaceuticals Ltd
7.3.1 Overview
7.3.2 Salix Pharmaceuticals product portfolio
7.3.3 SCOT Analysis
7.4 Synergy Pharmaceuticals Inc
7.4.1 Overview
7.4.2 Synergy Pharmaceuticals Product Portfolio
7.4.3 SCOT Analysis
7.5 Cubist Pharmaceuticals (Adolor Corporation) – A Subsidary Of Merck
7.5.1 Overview
7.5.2 Cubist Pharmaceuticals Product Portfolio
7.5.3 SCOT Analysis
7.6 Sucampo Pharmaceuticals
7.6.1 Overview
7.6.2 Sucampo Pharmaceuticals Product Portfolio
7.6.3 SCOT Analysis
7.7 Ironwood Pharmaceuticals, Inc.
7.7.1 Overview
7.7.2 Ironwood Pharmaceuticals Inc. Products Portfolio
7.7.3 SCOT Analysis
7.8 Daiichi Sankyo Co. Ltd.
7.8.1 Overview
7.8.2 Daiichi Sankyo Product Portfolio
7.8.3 SCOT Analysis
7.9 Pfizer
7.9.1 Overview
7.9.2 Pfizer Product Portfolio
7.9.3 SCOT Analysis
7.10 Progenics Pharmaceuticals Inc
7.10.1 Overview
7.10.2 Progenics Pharmaceuticals Product Portfolio
7.10.3 SCOT Analysis

List Of Table :

TABLE 1 Global OIC drug market by geography 2014-2022 (USD Mn)
TABLE 2 Pharmacological approaches to treat opiate-induced constipation
TABLE 3 Laxatives Used for Opioid-induced Constipation
TABLE 4 Common Side-effects of Using Laxatives
TABLE 5 Patients Unfit for Intake of Opioids
TABLE 6 Global OIC Drug Market, by Drug Type, 2014-2022(USD Mn)
TABLE 7 Global Product profile (Methylnaltrexone Bromide)
TABLE 8 Global Methylnaltrexone Bromide OIC Drug Market, by Geography 2014-2022 (USD Mn)
TABLE 9 Product Profile (Lubiprostone)
TABLE 10 Global Lubiprostone OIC Drug Market, by Geography, 2014-2022 (USDMn)
TABLE 11 Product profile: Naloxegol
TABLE 12 Naloxegol OIC drug market by geography 2014-2022 (USDMn)
TABLE 13 Pipeline Product Profile (Naldemedine)
TABLE 14 Pipeline Product Profile: Alvimopan, Dolcanatide
TABLE 15 Global OIC Drugs Market, by Prescription Type, 2014 (%)
TABLE 16 Global Prescribed OIC Drugs Market, by Prescription Type, 2014-2022 (USD Mn)
TABLE 17 U.S. OIC Drugs Market, by Drug Type, 2014-2022 (USD Mn)
TABLE 18 U.S. Prescribed OIC Drugs Market, by Prescription Type, 2014-2022 (USD Mn)
TABLE 19 Europe OIC Drugs Market, by Country, 2014-2022 (USD Mn) 

List Of Figure :

FIG. 1 Global OIC drugs market 2014-2022 (USD Mn)
FIG. 2 Global OIC Drugs Market by Drug Type, 2014 and 2020 (Value %)
FIG. 3 Global OIC Drugs Market, by Prescription Type, 2014 (%)
FIG. 4 Opioid Treatment Admissions and Sales, 1999-2010
FIG. 5 Opioid Prescription Statistics, 1993-2013 (USD Mn)
FIG. 6 Opioids Market: Growth Contributors
FIG. 7 Proportion of Population Aged 60 and Above, 2014
FIG. 8 Therapeutic Opioid Use in US (g/100,000 population)
FIG. 9 Common Side Effects of Movantik
FIG. 10 Considerations Taken for Opioid Usage
FIG. 11 Major Opioid Uses
FIG. 12 Global Methylnaltrexone Bromide OIC Drug Market 2014-2022 (USD Mn)
FIG. 13 Lubiprostone OIC Drug Market, 2014-2022 (USD Mn)
FIG. 14 Naloxegol OIC drug market 2014-2022 (USD Mn)
FIG. 15 Pipeline Product Profile: Elobixibat
FIG. 16 Global Prescribed OIC Drugs Market, 2014-2022 (USD Mn)
FIG. 17 Global Prescribed Branded OIC drug market 2014-2022 (USD Mn)
FIG. 18 Global Prescribed Generic OIC Drugs Market, 2014 - 2022 (USD Mn)
FIG. 19 Global Over the Counter OIC Drugs Market, 2014-2022 (USD Mn)
FIG. 20 North America OIC Drugs Market, 2014-2022 (USD Mn)
FIG. 21 North America OIC Drugs Market, by Country, 2014-2022 (USD Mn)
FIG. 22 U.S. OIC Drugs Market, 2014-2022 (USD Mn)
FIG. 23 U.S. OIC Drugs Market, by Prescription Type, 2014-2022 (USD Mn)
FIG. 24 Canada OIC Drugs Market, 2014-2022 (USD Mn)
FIG. 25 Total Number of Prescriptions Dispensed for Opioids in Canada, 2010-2014
FIG. 26 Europe OIC Drugs Market, 2014-2014 (USD Mn)
FIG. 27 U.K. OIC Drugs Market, 2014-2022 (%)
FIG. 28 Germany OIC Drugs Market, 2014-2022 (USD Mn)
FIG. 29 Rest of Europe OIC Drugs Market, 2014-2022 (USD Mn)
FIG. 30 Asia Pacific OIC Drugs Market, 2014-2022 (USD Mn)
FIG. 31 Asia Pacific OIC Drugs Market, by Country, 2014-2022 (USD Mn)
FIG. 32 China OIC Drugs Market, 2014-2022 (USD Mn)
FIG. 33 Japan OIC Drugs Market, 2014-2022 (USD Mn)
FIG. 34 APAC OIC Drugs Market, 2014-2022 (USD Mn)
FIG. 35 RoW OIC Drugs Market, by Region, 2014-2022 (USD Mn)
FIG. 36 Middle East and Africa OIC Drugs Market, 2014-2022 (USD Mn)
FIG. 37 Latin America OIC Drugs Market, 2014-2022 (USD Mn)
FIG. 38 Rest of RoW OIC Drugs Market, 2014-2022 (USD Mn)

Opioids induced constipation drugs are widely adopted in developed and emerging economies to enable patients in alleviating pain. Methylnaltrexone bromide, lubiprostone and naloxegol are the major drug types indicated for OIC treatment.

Opioid Induced Constipation (OIC) Market

Among these, methhylnaltrexone bromide (Relistor) is the largest drug segment in 2015. On the other hand, Lubiprostone is expected to take over the dominance of Relistor/methylnaltrexone bromide, though it’s brand-name Amitiza. Unlike methylnaaltrexone bromide, which is prescribed for OIC in advanced illnesses, lubiprostone is referred as a direct treatment for OIC. Naloxegol is another widely adopted OIC drugs for the treatment of constipation. It blocks certain effects of opioid medication. The segment is expected to progress at the fastest CAGR in the market during the forecast period. Its mechanism of action of treating OIC without reducing the pain relieving effects of opioids is the major factor contributing to the growth of naloxegol market. Europe, at present is the largest market for naloxegol drugs; however, North America will demonstrate the fastest market growth. Higher awareness among the patient population, and better reimbursement policies are the prime contributors to the OIC drugs market in the developed regions. Considering the pipeline drugs for OIC treatment, Naldemedine, Elobixibat, Alvimopan and Dolcanatide are the current pipeline drugs under phase 3 and phase 2 studies. Among these, naldemedine and elobixibat are currently under phase 3 studies and are expected commercialization within the forecast period.

For the purpose of this study, the global Opioid Induced Constipation (OIC) Drugs market is categorized into:

  • North America (US and Canada)
  • Europe (UK, Germany and Rest of Europe)
  • Asia Pacific (China, Japan and Rest of Asia Pacific)
  • Rest of the World (Middle East and Africa, and Latin America)

Opioid Induced Constipation (OIC) Market

In the base year 2015, North America and Europe together captured more than half of the global market revenue. Swift adoption of novel medications, higher reference to medical assistance, higher intake of opioids for pain relieving and better reimbursement policies are the prime contributors to the dominance of these regions. Expenditure on healthcare is highest in the US as compared to other nations. Per capita health expenditure in 2012 was USD 8,895 and total healthcare expenditure was 17.9% of GDP (2012). In 2014, the US government spent 17.9% of its GDP in healthcare that is the highest spending amongst all developed nations. The healthcare spending on individual citizen is estimated to be USD 8,608 per person. On the other hand, rapid adoption of pain relieving opioids for non-cancer ailments, improvement in awareness among general patient population and increasing improvement in availability of advanced medications are expected to contribute to the fastest growth of Asia Pacific OIC drugs market.

Based on prescription type, the global opioid induced constipation drugs market is segmented into prescription and OTC drugs market. Furthermore, the prescribed OIC drugs market is further studied for generic and branded OIC drugs.

Opioid Induced Constipation (OIC) Market

Branded OIC drugs are much adopted in developed economies such as US, UK, Germany, France, Spain and Canada. North America has highest contribution in OIC drug market by generic drugs market followed by Europe. There is huge demand for generic and over the counter drugs in US, UK, France, Spain, Germany, China, India and Indonesia. Lubiprostone, Naloxegol, methyl naltrexone are some common generic drugs which are adopted across the globe. Upcoming approval of phase 3 drugs for OIC treatment is expected to lead to an upsurge in demand for prescribed OIC drugs in the near future, particularly in the US and Europe markets. Asia Pacific is considered to be most emerging market and expected to contribute significantly in the next few years. AstraZeneca, Shionogi &Co., Ltd., Adolor Corporation, Synergy Pharmaceuticals Inc., Salix Pharmaceuticals, Inc., Sucampo AG are expected to contribute significantly in OIC market.

Hismation
Introduction of new OIC products, rapid FDA approvals and success in clinical trials have been the prime feature of OIC drugs market in the past. For instance, commercialization of Amitiza in the EU and Linzess were the major market events this creating growth opportunities in the OIC drugs market. Availability of such novel drugs has enables physician and patient awareness in constipation treatment market. On the other hand, high price of PAMORA and reimbursement issues in certain regions may hold the market growth.

The global OIC prevalence is expected to grow significantly over the forecast period due to significant adoption of opioids for treating chronic non-cancer pain. Growing elderly population and growth in healthcare spending are creating scope for global OIC drugs market. Asia Pacific is expected to emerge as a significant regional market. Poor eating habits and sedentary work style have been involved in constipation issues. Couple with this, regular consummation of opioids for mitigating chronic non-cancer pain further contribute to incidence of OIC. Developed nations such as Germany, UK, US, Spain and others are the most prominent national markets for OIC drugs. Factors such pregnancy, idle lifestyle and lack of required physical movements and intake of constipation causing pain-killers add to the demand for OIC drugs across the globe.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients